$30.07
0.76[2.59%]
At close: Apr 26
$30.07
0[0.00%]
After Hours: 4:20PM EDT
Supernus Pharmaceuticals
(NASDAQ:SUPN)Latest News for Supernus Pharmaceuticals Stock (NASDAQ:SUPN)
Supernus Pharmaceuticals Stock (NASDAQ: SUPN)
Categories: All
Monday, April 08, 2024
- Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's DiseaseVandana Singh - Apr 8, 2024, 10:11AM
- Supernus Pharmaceuticals shares are trading lower after the company announced the FDA has issued a Complete Response Letter in response to the company's New Drug Application for SPN-830.Benzinga Newsdesk - Apr 8, 2024, 8:20AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Apr 8, 2024, 8:09AM
- Supernus Provides Regulatory Update For SPN-830, FDA Has Issued A CRL In Response To The Co's NDA For Spn-830 Indicating That The Review Cycle For The Application Is Complete, But That The Application Is Not Ready For Approval In Its Present Form.Benzinga Newsdesk - Apr 8, 2024, 8:06AM
Wednesday, February 28, 2024
Tuesday, February 27, 2024
- Supernus Sees FY24 Total Revenue $580M-$620M vs $622.52M Est.Benzinga Newsdesk - Feb 27, 2024, 5:15PM
- Recap: Supernus Pharmaceuticals Q4 EarningsBenzinga Insights - Feb 27, 2024, 4:30PM
- Supernus Pharmaceuticals Q4 2023 Adj EPS $0.39 Misses $0.55 Estimate, Sales $164.31M Beat $155.03M EstimateBenzinga Newsdesk - Feb 27, 2024, 4:30PM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 05, 2024
Tuesday, December 12, 2023
Tuesday, November 21, 2023
Friday, November 17, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
- Supernus Pharmaceuticals Narrows FY23 Revenue From $580M-$620M To $590-$610 Vs $594.28M Est.Benzinga Newsdesk - Nov 8, 2023, 4:56PM
- Supernus Pharmaceuticals: Q3 Earnings InsightsBenzinga Insights - Nov 8, 2023, 4:30PM
- Supernus Pharmaceuticals Q3 2023 EPS $(0.29) Down From $(0.03) YoY, Revenue $153.9M Beats $143.387M EstimateBenzinga Newsdesk - Nov 8, 2023, 4:26PM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM
Wednesday, October 25, 2023
Monday, October 09, 2023
Tuesday, October 03, 2023
Monday, October 02, 2023
Thursday, September 21, 2023
Tuesday, September 19, 2023
Friday, September 15, 2023
Sunday, September 10, 2023
Tuesday, August 22, 2023
Tuesday, August 08, 2023
Friday, June 23, 2023
Wednesday, May 10, 2023
Tuesday, May 09, 2023
Monday, May 08, 2023
Tuesday, February 28, 2023
Monday, January 23, 2023
Thursday, December 01, 2022
Tuesday, November 08, 2022
Monday, October 10, 2022
- FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's TherapyVandana Singh - Oct 10, 2022, 9:27AM
- Supernus Pharmaceuticals shares are trading lower after the FDA issued a Complete Response Letter to the company's SPN-830.Luke J Jacobi - Oct 10, 2022, 8:35AM
- Supernus Provides Regulatory Update On SPN-830; Announced FDA Issued Complete Response Letter For SPN-830 New Drug ApplicationBenzinga Newsdesk - Oct 10, 2022, 8:32AM